Insider Selling: Clene (NASDAQ:CLNN) Major Shareholder Sells 9,075 Shares of Stock

by · The Cerbat Gem

Clene Inc. (NASDAQ:CLNN – Get Free Report) major shareholder Chidozie Ugwumba sold 9,075 shares of the firm’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $6.27, for a total value of $56,900.25. Following the transaction, the insider owned 741,292 shares in the company, valued at approximately $4,647,900.84. This trade represents a 1.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

  • On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The stock was sold at an average price of $5.50, for a total value of $179,877.50.
  • On Thursday, January 8th, Chidozie Ugwumba sold 3,195 shares of Clene stock. The shares were sold at an average price of $6.09, for a total value of $19,457.55.
  • On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The stock was sold at an average price of $6.29, for a total value of $24,770.02.
  • On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The stock was sold at an average price of $6.04, for a total value of $18,790.44.
  • On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The shares were sold at an average price of $5.87, for a total value of $34,451.03.
  • On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The stock was sold at an average price of $5.73, for a total transaction of $23,005.95.
  • On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The stock was sold at an average price of $5.81, for a total transaction of $76,081.95.
  • On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The shares were sold at an average price of $6.03, for a total transaction of $24,952.14.
  • On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The stock was sold at an average price of $5.95, for a total transaction of $48,171.20.
  • On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The shares were sold at an average price of $6.27, for a total transaction of $42,830.37.

Clene Stock Performance

Shares of Clene stock traded down $1.21 during trading on Monday, reaching $5.18. The company’s stock had a trading volume of 359,860 shares, compared to its average volume of 108,848. The business’s fifty day moving average price is $7.68 and its 200-day moving average price is $6.44. The firm has a market cap of $53.53 million, a price-to-earnings ratio of -1.53 and a beta of 0.87. Clene Inc. has a one year low of $2.28 and a one year high of $13.50.

Clene (NASDAQ:CLNN – Get Free Report) last announced its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.06 million. Sell-side analysts anticipate that Clene Inc. will post -5.19 EPS for the current year.

Institutional Investors Weigh In On Clene

A number of hedge funds have recently added to or reduced their stakes in CLNN. Jones Financial Companies Lllp acquired a new stake in Clene during the 3rd quarter worth $29,000. Jane Street Group LLC acquired a new stake in shares of Clene during the second quarter worth $47,000. Lunt Capital Management Inc. increased its holdings in Clene by 71.2% in the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after purchasing an additional 21,217 shares during the last quarter. Finally, Scoggin Management LP lifted its stake in Clene by 42.8% in the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after buying an additional 42,750 shares during the period. Institutional investors own 23.28% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on CLNN shares. Benchmark reaffirmed a “buy” rating on shares of Clene in a research report on Thursday, December 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a report on Tuesday, October 14th. UBS Group reiterated a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Finally, D. Boral Capital reissued a “buy” rating and set a $23.00 target price on shares of Clene in a research report on Friday. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $32.60.

Get Our Latest Report on Clene

Clene Company Profile

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Featured Stories